Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: Cacaito who wrote (21504)	4/29/1999 10:50:00 AM
From: DaiS	Read Replies (1) \| Respond to of 23519

Muse does you good! Caicaito, That's interesting...here another couple of very recent references about PGE-1...no idea what they mean mind you! DaiS (1) TI: Embolia cutis medicamentosa of the foot after sclerotherapy AU: Geukens_J, Rabe_E, Bieber_T NA: UNIV HOSP,DEPT DERMATOL,SIGMUND FREUD STR 25,D-53105 BONN,GERMANY JN: EUROPEAN JOURNAL OF DERMATOLOGY, 1999, Vol.9, No.2, pp.132-133 IS: 1167-1122 DT: Article AB: Typically, embolia cutis medicamentosa is reported after intramuscular injections of drugs. We describe a case of embolia cutis medicamentosa after sclerotherapy of intracutaneous veins of the foot with a polidocanol solution of 1%. Under therapy with intravenous alprostadil, pentoxifyllin, internal steroids and anticoagulation with heparin, the lesions healed completely without necrosis. WA: embolia cutis medicamentosa, intracutaneous veins, necrosis, Nicolau, polidocanol, sclerotherapy (2) TI: Clinical and haemostatic effects of intravenous prostaglandin E1 therapy in patients with peripheral arterial occlusive disease AU: Trifiletti_A, Scamardi_R, Pizzoleo_MA, Sottilotta_G, Soraci_S, Attina_A, Bagnato_L, Barbera_N NA: VIA MONSIGNOR DARRIGO 23,I-98121 MESSINA,ITALY UNIV MESSINA,DEPT INTERNAL MED,I-98100 MESSINA,ITALY JN: PANMINERVA MEDICA, 1999, Vol.41, No.1, pp.15-17 IS: 0031-0808 DT: Article AB: Background. In this study the action of an antiaggregatory prostaglandin, PGE1, was studied in a group of patients with peripheral arterial occlusive disease (PAOD), Methods. In 16 patients with PAOD Fontaine stage IIb and III the clinical and haemostatic effects of the endovenous administration of 60 mu g/die of alwprostadil-PGE1 for four weeks, were evaluated. Before and after pharmacological treatment, were evaluated the clinical symptoms (claudicatio intermittens and rest pain) and the following haemostatic parameters: plasma thrombomodulin (TM), beta-thromboglobulin (beta-TG), D-dimer (DD), tissue-type plasminogen activator (t- PA) and plasminogen activator-inhibitor (PAI-1). Results. No significant difference in plasma TM, t-PA and PAI-1 levels was observed after the treatment. On the other hand the patients showed plasma levels of beta-TG and DD significantly decreased at the end of the treatment. From the clinical point of view both claudicatio intermittens and rest pain satisfactorily improved in all patients. Conclusions. This data confirmed the therapeutic efficacy of PGE1 in the treatment of PAOD patients. WA: arterial occlusive disease, blood coagulation, alprostadil ** End of Data **